Burkholderia Pseudomallei Infections - Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Burkholderia Pseudomallei Infections - Pipeline Review, H1 2015’, provides an overview of the Burkholderia Pseudomallei Infections’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Burkholderia Pseudomallei Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkholderia Pseudomallei Infections and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Burkholderia Pseudomallei Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Burkholderia Pseudomallei Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Burkholderia Pseudomallei Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Burkholderia Pseudomallei Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Burkholderia Pseudomallei Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Burkholderia Pseudomallei Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Introduction
- Global Markets Direct Report Coverage
- Burkholderia Pseudomallei Infections Overview
- Therapeutics Development
- Pipeline Products for Burkholderia Pseudomallei Infections - Overview
- Pipeline Products for Burkholderia Pseudomallei Infections - Comparative Analysis
- Burkholderia Pseudomallei Infections - Therapeutics under Development by Companies
- Burkholderia Pseudomallei Infections - Therapeutics under Investigation by Universities/Institutes
- Burkholderia Pseudomallei Infections - Pipeline Products Glance
- Early Stage Products
- Burkholderia Pseudomallei Infections - Products under Development by Companies
- Burkholderia Pseudomallei Infections - Products under Investigation by Universities/Institutes
- Burkholderia Pseudomallei Infections - Companies Involved in Therapeutics Development
- Bavarian Nordic A/S
- Emergent BioSolutions Inc.
- Soligenix, Inc.
- Syntiron LLC
- Burkholderia Pseudomallei Infections - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Burkholderia pseudomallei vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- burkholderia vaccine - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- dusquetide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GC-072 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SGX-101 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SGX-943 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit FtsZ Protein for Bacterial Infections - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Burkholderia Pseudomallei Infections - Recent Pipeline Updates
- Burkholderia Pseudomallei Infections - Dormant Projects
- Burkholderia Pseudomallei Infections - Discontinued Products
- Burkholderia Pseudomallei Infections - Product Development Milestones
- Featured News & Press Releases
- Feb 11, 2015: Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC
- Aug 14, 2014: US DTRA to fund preclinical work on Evolva’s antibiotic GC-072
- Feb 14, 2014: Soligenix Announces $300,000 NIAID SBIR Grant Award Supporting Further Evaluation of SGX943 as a Treatment for Melioidosis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Burkholderia Pseudomallei Infections, H1 2015
- Number of Products under Development for Burkholderia Pseudomallei Infections - Comparative Analysis, H1 2015
- Number of Products under Development by Companies, H1 2015
- Number of Products under Investigation by Universities/Institutes, H1 2015
- Comparative Analysis by Early Stage Development, H1 2015
- Products under Development by Companies, H1 2015
- Products under Investigation by Universities/Institutes, H1 2015
- Burkholderia Pseudomallei Infections - Pipeline by Bavarian Nordic A/S, H1 2015
- Burkholderia Pseudomallei Infections - Pipeline by Emergent BioSolutions Inc., H1 2015
- Burkholderia Pseudomallei Infections - Pipeline by Soligenix, Inc., H1 2015
- Burkholderia Pseudomallei Infections - Pipeline by Syntiron LLC, H1 2015
- Assessment by Monotherapy Products, H1 2015
- Number of Products by Stage and Target, H1 2015
- Number of Products by Stage and Mechanism of Action, H1 2015
- Number of Products by Stage and Route of Administration, H1 2015
- Number of Products by Stage and Molecule Type, H1 2015
- Burkholderia Pseudomallei Infections Therapeutics - Recent Pipeline Updates, H1 2015
- Burkholderia Pseudomallei Infections - Dormant Projects, H1 2015
- Burkholderia Pseudomallei Infections - Discontinued Products, H1 2015
- List of Figures
- Number of Products under Development for Burkholderia Pseudomallei Infections - Comparative Analysis, H1 2015
- Comparative Analysis by Early Stage Products, H1 2015
- Number of Products by Top 10 Targets, H1 2015
- Number of Products by Stage and Top 10 Targets, H1 2015
- Number of Products by Top 10 Mechanism of Actions, H1 2015
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
- Number of Products by Top 10 Routes of Administration, H1 2015
- Number of Products by Stage and Top 10 Routes of Administration, H1 2015
- Number of Products by Top 10 Molecule Types, H1 2015